UK pharma sector stays immune to Brexit as innovation, scale spur deals

London

AS the United Kingdom's vote to leave the European Union wreaks havoc on the British economy, dealmaking momentum in the country's pharmaceutical industry is showing no signs of letting up.

Healthcare acquisitions in the UK have risen 21 per cent this year as total mergers and acquisitions (M&A) fell 43 per cent in Britain and dropped 16 per cent worldwide, according to data compiled by Bloomberg.